InfeXtious Therapeutics

Infex Therapeutics is a clinical-stage biotechnology company based in the United Kingdom, dedicated to developing innovative therapies for critical-priority infectious diseases and antimicrobial resistance (AMR). Originally established as The AMR Centre, the company operates a translational R&D model, acquiring promising early-stage assets and advancing them through clinical proof of concept. Its lead candidate, RESP-X, is a first-in-class monoclonal antibody currently in Phase 2a trials for the prevention of Pseudomonas aeruginosa infections in patients with non-cystic fibrosis bronchiectasis. The company's pipeline also includes MET-X, a small molecule metallo-beta-lactamase inhibitor for drug-resistant Gram-negative infections, and several preclinical programs targeting gonorrhoea and viral threats like COVID-19. Infex leverages strategic partnerships with global pharmaceutical companies and academic institutions to accelerate the delivery of new anti-infectives to the market.